Acquisition strengthens Spectrum’s strategic and commercial offering, allowing for differentiated positioning to be pulled through via best-in-class agile delivery model
Spectrum Science, an independent, full-service, strategic platform offering integrated healthcare marketing communications, clinical trial recruitment and retention, advertising, consulting and media services announced the acquisition of Return on Focus, a strategic marketing organization that helps pharmaceutical and biotech companies create value for their brands through a proprietary, evidence-based approach to positioning and other foundational strategic services.
For more than 20 years Return on Focus has applied a rigorous methodology that integrates deep internal expertise, comprehensive market research and thorough competitive analysis into a proprietary framework that delivers the foundational insights and communication elements necessary to support optimal launch trajectory and ongoing brand success. This structured, evidence-based process empowers organizations to act decisively and confidently in dynamic markets, where early strategic choices set the stage to unlock a brand’s full commercial potential and market impact.
Marketing Technology Insights: Skanteq Launches Affordable Code-Free AR Platform for Businesses and Marketers
“The acquisition of Return on Focus is a natural extension of Spectrum’s commitment to delivering unmatched strategic value to our clients,” said Amy Hutnik, President and Chief Commercial Officer of Spectrum Science. “Return on Focus’ data-driven positioning expertise adds specificity and depth to our integrated approach, bridging the gap between early clinical development and commercial strategy. This partnership strengthens our ability to guide products to market with precision, helping both Spectrum and Return of Focus clients benefit from our combined acumen and expanded service offerings.”
Return on Focus operates in complex, high-impact therapeutic areas including oncology, immunology and rare disease across a diverse range of pharmaceutical, biotechnology and specialty care companies. Over the past five years, Return on Focus has worked with more than 40 companies, including seven of the top 10 pharmaceutical companies. In joining with Spectrum, Dan Reinhardt and Abby Manning will continue leading the Return on Focus team, working closely with Spectrum’s Advertising, Communications and Consulting teams.
Marketing Technology Insights: Evoke Strategy Launches Full-Funnel Digital PR to Prove ROI and Impact
“At Spectrum, we’ve found an ideal collaborator in an organization that shares our commitment to applying scientific and strategic acumen to optimize our client’s commercial success,” said Dan Reinhardt, President of Return on Focus. “With our unique lens and commitment to evidence-based decision-making, we’re able to disrupt the status quo and unlock value for our clients. Together with Spectrum, we can ensure that the value we create is carried through every phase of a product’s lifecycle, delivering measurable impact for our clients.”
Marketing Technology Insights: Later Unveils New Social Media Tools at Quarterly Showcase The Drop
Source – PR Newswire
For media inquiries, you can write to our MarTech Newsroom at sudipto@intentamplify.com
